ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / FBIO / options
CPIX (37) ZYBT (41) QUCY (28) SDEV (33) ⌘ Pro Terminal β†’

Fortress Biotech Inc. (FBIO) Options Positioning, Max Pain & Unusual Sweeps

$1.93 +0.52% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.93

Fortress Biotech Inc. (FBIO) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $64.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FBIO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is FBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Fortress Biotech Inc. (NASDAQ: FBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.93 (+0.52% 1D, market cap $64.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, FBIO ranks #803 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does FBIO compare to CPIX and ZYBT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBIO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 66.9%, and ROIC of -35.0%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -16.4%, cap $63.2M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (41/100 RQD, P/E N/A, ROIC -22.3%, cap $63.0M). Among the 5-stock peer group, FBIO leads on earnings multiple (N/A) while CPIX leads on capital efficiency (-16.4% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FBIO?
β–Ό

Per FBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001429260), Fortress Biotech Inc. generated $63.3M in revenue (+9.7% YoY), $37.0M in net income, and -$65.8M in free cash flow against $185.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.93 (-0.10%)🧬 Disciplined Float (+0.16% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (30/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (4)Whales (3)SEC (10)Macro (6)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-12.4% Base Target
$5 Bull$2 Base$1 Bear
πŸ“¬ FREE FBIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for FBIO)Realized 20D OHLCV Swing Band: Β±8.4%
Deterministic 5-Pillar Attribution (30/100 Composite)
πŸ” WHY FBIO SCORES 30/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy β€’ Disciplined Float (+0.16% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$1.95-0.5% Next Q
Q2 (-2Q)
35
Grade E$1.94-0.5% Next Q
Q3 (-1Q)
33
Grade E$1.93+0% Next Q
Current
30
Grade E$1.93-9.6% Hist 90D Ξ±
Trajectory: E (38) β†’ E (30)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a FBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While FBIO currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.27) and Max Pain ($2.03) forces dealer call-delta covering toward $4.76.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FBIOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œFBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±8.4%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (FBIO)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for FBIO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FBIO)

  • βœ“Walkthrough of FBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
FBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.54%⚑ TESTING RESISTANCE
2026-11-04O $1.92H $1.93L $1.92C $1.93VOL 198.2K
RES: $2.01SUP: $1.66SMA50: $2.27SMA200: $2.77
$3.98$3.40$2.81$2.23$1.65RES $2.01SUP $1.66$1.932026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ FBIO Butterfly Map β†’ + Track FBIO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +9.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FBIO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for FBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FBIO)

Health Care Rank #803 of 1015 βš”οΈ CPIX vs FBIO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (FBIO vs. CPIX, ZYBT, QUCY, SDEV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Fortress Biotech Inc. (FBIO) ranks #803 by composite RQD confidence (30/100, grade E) and #708 by equity capitalization ($64.4M). Within this direct 5-issuer industry benchmark cohort, FBIO leads on earnings valuation at N/A trailing P/E, while CPIX leads on capital efficiency and profitability with -16.4% ROIC and 85.0% gross margin. ZYBT currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with FBIO at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FBIO ACTIVE
Fortress Biotech Inc.
E 30/100 β€” 66.9% -35.0% +0.52% $64.4M Benchmark Subject
CPIX
Cumberland Pharmaceuticals Inc.
D- 37/100 β€” 85.0% -16.4% -10.02% $63.2M /cpix-vs-fbio β†’
ZYBT
Zhengye Biotechnology Holding Limited (Class A)
D- 41/100 β€” 20.5% -22.3% +2.31% $63.0M /zybt-vs-fbio β†’
QUCY
Quantum Cyber N.V.
E 28/100 β€” 72.6% -35.0% -9.61% $66.2M /qucy-vs-fbio β†’
SDEV
Stablecoin Development Corporation
E 33/100 β€” β€” -35.0% -8.91% $67.3M /sdev-vs-fbio β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001429260 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fortress Biotech Inc. (FBIO) reported GAAP revenue of $63.3M (+9.7% vs. FY2024 revenue of $57.7M , and -25.1% cumulative change since FY2023) , GAAP net income of $37.0M, operating cash flow of -$65.8M, and free cash flow of -$65.8M (+18.0% YoY). On the balance sheet, FBIO closed FY2025 with $185.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $63.3M $37.0M -$65.8M -$65.8M $185.5M β€”
FY2024 (FY) 2024-12-31 $57.7M $21.0M -$80.2M -$80.2M $144.2M β€”
FY2023 (FY) 2023-12-31 $84.5M $31.0M -$128.2M -$128.2M β€” β€”

3. FBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Fortress Biotech Inc. (NASDAQ: FBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.93 (+0.52% 1D, market cap $64.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, FBIO ranks #803 in composite RQD confidence.

How does FBIO compare to CPIX and ZYBT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBIO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 66.9%, and ROIC of -35.0%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -16.4%, cap $63.2M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (41/100 RQD, P/E N/A, ROIC -22.3%, cap $63.0M). Among the 5-stock peer group, FBIO leads on earnings multiple (N/A) while CPIX leads on capital efficiency (-16.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FBIO?

Per FBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001429260), Fortress Biotech Inc. generated $63.3M in revenue (+9.7% YoY), $37.0M in net income, and -$65.8M in free cash flow against $185.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

FBIO last traded at $1.93 (+0.52% on volume of 198,163 shares), positioning the stock -14.98% below its 50-day simple moving average ($2.27) and -30.32% below its 200-day simple moving average ($2.77). Across its 52-week range of $1.83 to $4.53, FBIO sits at the 3.7% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of Β±8.4% ($1.77 to $2.09).

Direct Sub-Reports: FBIO RQD Cockpit FBIO 12M Forecast FBIO Earnings & Move FBIO Dividends & DRIP FBIO Insiders & 13F FBIO Whale Options FBIO Profit Sankey FBIO News & Why
ROARABLE RATING BRIEF β€’ RQD 30/100 (E) βœ“ SEC XBRL & RQD VERIFIED

FBIO β€” Fortress Biotech Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Fortress Biotech Inc. (FBIO) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.93 (+0.52% 1D, market capitalization $64.4M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 66.9%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Fortress Biotech Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. β€” for product lines, customer base, or revenue model detail. The profile records a market capitalization of $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Fortress Biotech Inc. (FBIO) reported $63.3M in annual revenue (up from $57.7M in FY2024, +9.7% YoY) and $37.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($84.5M revenue, $31.0M net income) through FY2025, FBIO scaled operating cash flow to -$65.8M and free cash flow to -$65.8M, backed by $185.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.83 – $4.53 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), FBIO carries a macro regime beta of 1.00 and gross margin of 66.9%.

  • Key Question #1: Can FBIO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $63.3M and free cash flow of -$65.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FBIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Fortress Biotech Inc. (FBIO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to FBIO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FBIO Bull vs. Bear Conversation Board β€” What's Your Call at $1.93?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FBIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FBIO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER β€’ Verified $100K Arena Trader πŸ‚ BULLISH 🎯 Target: $2.40 (+25.0%)
πŸ“Œ Pinned Debate

Reported cash rose to $79.4M in FY 2025 and the reported repayment of USD 15.00 million in debt, alongside a Piotroski F-Score of 5/9 a

Don't sleep on FBIO's setup in Health Care. Reported cash rose to $79.4M in FY 2025 and the reported repayment of USD 15.00 million in debt, alongside a Piotroski F-Score of 5/9 and Altman Z-Score of 2.5, points to a balance sheet that is not in acute distress.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (30/100) backs up the fundamental quality.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” FBIO's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.63 (-15.1%)
Spot @ $1.92

Operating income was negative in every reported period (-$70.2M in FY 2025) with ROIC at -35% and FCF yield at 0%, so the business is n

Fading this rally in FBIO at $1.92. Operating income was negative in every reported period (-$70.2M in FY 2025) with ROIC at -35% and FCF yield at 0%, so the business is not currently generating returns or free cash flow for shareholders.. With a beta of 1.0 and the stock sitting at $1.92 (52-wk range $1.83–$4.53), the easy multiple expansion is already priced in.

LIVE TAPE